In June 2018, ContraFect Corp. (CFRX) had multiple presentations at the American Society for Microbiology (ASM) Microbe 2018 on the company’s lead drug candidate CF-301 and the Gram-negative ...

Odor-causing bacteria in armpits targeted using bacteriophage-derived lysin. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2024 / 04 / 240423113115.htm ...

F12 is the first lysin-based treatment with the potential to be used multiple times on a single patient, making it ideal to treat particularly persistent drug-resistant and drug-sensitive infections.

The team then synthesized a lysin from a bacteriophage, or virus that attacks bacteria, that infects S. hominis. During in vitro experiments, this lysin was found to target only S. hominis , not ...

The research team’s paper, titled “Novel Phage Lysin Abp013 against Acinetobacter baumannii”, has been published in peer-reviewed, open-access journal Antibiotics. We trust that this news ...

Dr. Mya Thandar, Director, Zeus™-LysiThru™, noted that "Our established and proprietary tools in bioinformatics, machine-learning, and AI (Zeus™-LysiThru™) leverage high-throughput lysin ...